NYSE:BIOLife Sciences
Bio Rad Laboratories Q3 Loss Of US$12.70 EPS Tests Recovery Narrative For BIO Stock
Bio-Rad Laboratories (BIO) has put up a mixed set of numbers for Q3 FY 2025, with revenue of US$653 million and a basic EPS loss of US$12.70, against a backdrop of prior quarters that ranged from EPS of US$23.37 on US$649.7 million of revenue in Q3 FY 2024 to a loss of US$25.57 on US$667.48 million of revenue in Q4 FY 2024. Over the past few quarters, revenue has generally sat in the US$585 million to US$667 million band, while EPS has swung sharply between gains and losses. Investors will...